- Home
- PFL vs CRVS Comparison
PFL vs CRVS Comparison
Compare PFL & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFL
- CRVS
- Stock Information
- Founded
- PFL 2003
- CRVS 2014
- Country
- PFL United States
- CRVS United States
- Employees
- PFL N/A
- CRVS N/A
- Industry
- PFL Finance Companies
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- PFL Finance
- CRVS Health Care
- Exchange
- PFL Nasdaq
- CRVS Nasdaq
- Market Cap
- PFL 329.9M
- CRVS 335.1M
- IPO Year
- PFL N/A
- CRVS 2016
- Fundamental
- Price
- PFL $8.48
- CRVS $4.19
- Analyst Decision
- PFL
- CRVS Strong Buy
- Analyst Count
- PFL 0
- CRVS 5
- Target Price
- PFL N/A
- CRVS $12.38
- AVG Volume (30 Days)
- PFL 113.7K
- CRVS 419.4K
- Earning Date
- PFL 01-01-0001
- CRVS 03-18-2025
- Dividend Yield
- PFL 11.53%
- CRVS N/A
- EPS Growth
- PFL N/A
- CRVS N/A
- EPS
- PFL N/A
- CRVS N/A
- Revenue
- PFL N/A
- CRVS N/A
- Revenue This Year
- PFL N/A
- CRVS N/A
- Revenue Next Year
- PFL N/A
- CRVS N/A
- P/E Ratio
- PFL N/A
- CRVS N/A
- Revenue Growth
- PFL N/A
- CRVS N/A
- 52 Week Low
- PFL $6.98
- CRVS $1.30
- 52 Week High
- PFL $8.62
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- PFL 48.84
- CRVS 28.71
- Support Level
- PFL $8.45
- CRVS $4.60
- Resistance Level
- PFL $8.60
- CRVS $5.19
- Average True Range (ATR)
- PFL 0.05
- CRVS 0.30
- MACD
- PFL -0.00
- CRVS -0.06
- Stochastic Oscillator
- PFL 34.21
- CRVS 2.01
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).